Inter occasion variability in individual optimal design

被引:7
作者
Kristoffersson, Anders N. [1 ]
Friberg, Lena E. [1 ]
Nyberg, Joakim [1 ]
机构
[1] Uppsala Univ, Dept Pharmaceut Biosci, S-75124 Uppsala, Sweden
关键词
Inter occasion variability (IOV); Optimal design (OD); Maximum a posteriori (MAP); Fisher information; Bayesian; Pharmacometrics; Shrinkage; POPULATION PHARMACOKINETICS; SAMPLING STRATEGIES; MODELS; PREDICTION; PARAMETERS; COLISTIN; CRITERIA; NONMEM;
D O I
10.1007/s10928-015-9449-6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Inter occasion variability (IOV) is of importance to consider in the development of a design where individual pharmacokinetic or pharmacodynamic parameters are of interest. IOV may adversely affect the precision of maximum a posteriori (MAP) estimated individual parameters, yet the influence of inclusion of IOV in optimal design for estimation of individual parameters has not been investigated. In this work two methods of including IOV in the maximum a posteriori Fisher information matrix (FIMMAP) are evaluated: (i) MAP(occ)-the IOV is included as a fixed effect deviation per occasion and individual, and (ii) POPocc-the IOV is included as an occasion random effect. Sparse sampling schedules were designed for two test models and compared to a scenario where IOV is ignored, either by omitting known IOV (Omit) or by mimicking a situation where unknown IOV has inflated the IIV (Inflate). Accounting for IOV in the FIMMAP markedly affected the designs compared to ignoring IOV and, as evaluated by stochastic simulation and estimation, resulted in superior precision in the individual parameters. In addition MAP(occ) and POPocc accurately predicted precision and shrinkage. For the investigated designs, the MAP(occ) method was on average slightly superior to POPocc and was less computationally intensive.
引用
收藏
页码:735 / 750
页数:16
相关论文
共 24 条
  • [1] Atkinson A. C., 1992, OXFORD STAT SCI SERI, V8
  • [2] Beal SS, 1989, NONMEM User's Guides
  • [3] Prediction of Shrinkage of Individual Parameters Using the Bayesian Information Matrix in Non-Linear Mixed Effect Models with Evaluation in Pharmacokinetics
    Combes, Francois Pierre
    Retout, Sylvie
    Frey, Nicolas
    Mentre, France
    [J]. PHARMACEUTICAL RESEARCH, 2013, 30 (09) : 2355 - 2367
  • [4] Colistin: The revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections
    Falagas, ME
    Kasiakou, SK
    [J]. CLINICAL INFECTIOUS DISEASES, 2005, 40 (09) : 1333 - 1341
  • [5] Application of the Optimal Design Approach to Improve a Pretransplant Drug Dose Finding Design for Ciclosporin
    Hennig, Stefanie
    Nyberg, Joakim
    Fanta, Samuel
    Backman, Janne T.
    Hoppu, Kalle
    Hooker, Andrew C.
    Karlsson, Mats O.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (03) : 347 - 360
  • [6] Target concentration intervention: beyond Y2K
    Holford, NHG
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 48 (01) : 9 - 13
  • [7] Comparison of some practical sampling strategies for population pharmacokinetic studies
    Jonsson, EN
    Wade, JR
    Karlsson, MO
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1996, 24 (02): : 245 - 263
  • [8] Standard Error of Empirical Bayes Estimate in NONMEM® VI
    Kang, Dongwoo
    Bae, Kyun-Seop
    Houk, Brett E.
    Savic, Radojka M.
    Karlsson, Mats O.
    [J]. KOREAN JOURNAL OF PHYSIOLOGY & PHARMACOLOGY, 2012, 16 (02) : 97 - 106
  • [9] THE IMPORTANCE OF MODELING INTEROCCASION VARIABILITY IN POPULATION PHARMACOKINETIC ANALYSES
    KARLSSON, MO
    SHEINER, LB
    [J]. JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1993, 21 (06): : 735 - 750
  • [10] Evaluation of IPPSE, an alternative method for sequential population PKPD analysis
    Lacroix, B. D.
    Friberg, L. E.
    Karlsson, M. O.
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2012, 39 (02) : 177 - 193